Covid-19 Impact on Internal Neurostimulation Devices Market, Global Research Reports 2020-2021

The Internal Neurostimulation Devices is implanted in the body. It contains a battery that powers the entire system and is controlled by the nerve stimulator to send out electrical signals.

This report provides a complete quantitative data and qualitative analysis on the global market for Internal Neurostimulation Devices. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.

Prior to COVID-19, the global market for Internal Neurostimulation Devices was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Internal Neurostimulation Devices is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.

This report covers market size and forecasts of Internal Neurostimulation Devices, including the following market information:

Global Internal Neurostimulation Devices Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)

Global Internal Neurostimulation Devices Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)

Global Internal Neurostimulation Devices Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)

Global Internal Neurostimulation Devices Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

Key market players

Major competitors identified in this market include Stimwave, Boston Scientific, LivaNova, Abbott, Nexeon Medsytems, NeuroSigma, Synergia Medical, Medtronic, etc.

Based on the Region:

Asia-Pacific (China, Japan, South Korea, India and ASEAN)

North America (US and Canada)

Europe (Germany, France, UK and Italy)

Rest of World (Latin America, Middle East & Africa)

Based on the Type:

Neurostimulators

Implantable Cardiac Pacemakers

Cochlear Implants

Ventricular Assist Devices

Others

Based on the Application:

Hospitals and Clinics

Ambulatory Surgical Centers

Specialty Clinics

Others

 

 

The tourniquet market is projected to attain revenue equivalent to $475.62 Million by 2025

The tourniquet market in recent times has been displaying a steady expansion as a result of the higher frequency of road accidents, coupled with government efforts aimed at providing healthcare facilities and infrastructure in emerging economies. By 2025, the market is projected to attain revenue equivalent to $475.62 Million, which was estimated $201.76 Million in 2015. A promising CAGR of 9.3% will provide significant opportunities during the forecast period 2015-2025.

Intracranial pressure monitors market is poised to reach US$1.85 bn by 2025

Traumatic brain injuries and strokes remain one of the leading causes of death and disability across the globe. The upswing in the cases of brain injuries in adults as well as children has proved to be a shot in the arm for the global intracranial pressure monitors market. The Centers for Disease Control and Prevention states that every day nearly 140 people in the U.S. die from injuries that are associated with traumatic brain injuries.  According to a report by Crystal Market Reports, the opportunity in the global intracranial pressure monitors market was pegged at $1 Billion in 2015 and is poised to reach US$1.85 bn by 2025, rising at a CAGR of 6.30% between 2015 and 2025. A CMR analyst states that the sweeping shift towards non-invasive pressure monitors from invasive ones is likely to have a positive and enduring impact on the dynamics of the market.

Ginkgo Highly Optimistic to Launch New Spinoff Motif as Future Food

Ginkgo Bioworks, a company with a dream to become the biggest Amazon Web Services bio- manufacturer, has launched a new spinoff. Their latest spinoff, Motif Ingredients aimed at developing proteins which can replace meat and dairy proteins. Launching Motif is the second spinout for Ginkgo after successfully introducing Jyon Bio, developing a crop yields improving bacteria. However Ginkgo’s move in introducing animal protein replacements helped alternative meat and dairy companies, who wanted to reduce animal husbandry. Ginkgo ensures the success of their new endeavor through adding $90mn in funding from industry insiders such as Fonterra. Furthermore, a longtime veteran, Mclntyre has said that there’s now an opportunity to cater the challenge in inadequate protein supplies. With the goal of creating proteins at low cost, Ginkgo’s Motif satisfies the craving for proteins of growing population.